These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 32063434)
1. Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland. Sigurdsson S; Eythorsson E; Erlendsdóttir H; Hrafnkelsson B; Kristinsson KG; Haraldsson Á Vaccine; 2020 Mar; 38(12):2707-2714. PubMed ID: 32063434 [TBL] [Abstract][Full Text] [Related]
2. Reduction in All-Cause Acute Otitis Media in Children <3 Years of Age in Primary Care Following Vaccination With 10-Valent Pneumococcal Haemophilus influenzae Protein-D Conjugate Vaccine: A Whole-Population Study. Sigurdsson S; Eythorsson E; Hrafnkelsson B; Erlendsdóttir H; Kristinsson KG; Haraldsson Á Clin Infect Dis; 2018 Sep; 67(8):1213-1219. PubMed ID: 29617959 [TBL] [Abstract][Full Text] [Related]
3. Impact of the 10-valent pneumococcal conjugate vaccine on antimicrobial prescriptions in young children: a whole population study. Eythorsson E; Sigurdsson S; Hrafnkelsson B; Erlendsdóttir H; Haraldsson Á; Kristinsson KG BMC Infect Dis; 2018 Oct; 18(1):505. PubMed ID: 30286726 [TBL] [Abstract][Full Text] [Related]
4. The impact and cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the paediatric immunisation programme in Iceland-A population-based time series analysis. Eythorsson E; Ásgeirsdóttir TL; Erlendsdóttir H; Hrafnkelsson B; Kristinsson KG; Haraldsson Á PLoS One; 2021; 16(4):e0249497. PubMed ID: 33831049 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model. Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea. Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905 [TBL] [Abstract][Full Text] [Related]
7. Comparison of Serotype Prevalence of Pneumococci Isolated from Middle Ear, Lower Respiratory Tract and Invasive Disease Prior to Vaccination in Iceland. Hjálmarsdóttir MÁ; Quirk SJ; Haraldsson G; Erlendsdóttir H; Haraldsson Á; Kristinsson KG PLoS One; 2017; 12(1):e0169210. PubMed ID: 28125588 [TBL] [Abstract][Full Text] [Related]
8. Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children. Nair H; Watts AT; Williams LJ; Omer SB; Simpson CR; Willocks LJ; Cameron JC; Campbell H BMC Infect Dis; 2016 Aug; 16():390. PubMed ID: 27506837 [TBL] [Abstract][Full Text] [Related]
9. Estimated Annual Health and Cost Impact of PHiD-CV Immunization Program in Brazil. Gomez JA; Lopes de Abreu AJ; Caceres DC; Nieto J; Ortega-Barria E Pediatr Infect Dis J; 2019 Oct; 38(10):e260-e265. PubMed ID: 31568144 [TBL] [Abstract][Full Text] [Related]
10. Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control. Thorrington D; Andrews N; Stowe J; Miller E; van Hoek AJ BMC Med; 2018 Feb; 16(1):13. PubMed ID: 29415741 [TBL] [Abstract][Full Text] [Related]
11. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014. Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682 [TBL] [Abstract][Full Text] [Related]
12. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. Rinta-Kokko H; Palmu AA; Auranen K; Nuorti JP; Toropainen M; Siira L; Virtanen MJ; Nohynek H; Jokinen J Vaccine; 2018 Apr; 36(15):1934-1940. PubMed ID: 29526371 [TBL] [Abstract][Full Text] [Related]
13. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model. De Wals P; Black S; Borrow R; Pearce D Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience. Mrkvan T; Pelton SI; Ruiz-Guiñazú J; Palmu AA; Borys D Expert Rev Vaccines; 2018 Sep; 17(9):797-818. PubMed ID: 30185083 [TBL] [Abstract][Full Text] [Related]
15. The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions. Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C Hum Vaccin Immunother; 2021 Feb; 17(2):517-526. PubMed ID: 32574101 [TBL] [Abstract][Full Text] [Related]
16. Recurrent invasive pneumococcal disease in children--host factors and vaccination response. Ingels HA Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183055 [TBL] [Abstract][Full Text] [Related]
17. Reduction of antimicrobial resistant pneumococci seven years after introduction of pneumococcal vaccine in Iceland. Hjálmarsdóttir MÁ; Haraldsson G; Quirk SJ; Haraldsson Á; Erlendsdóttir H; Kristinsson KG PLoS One; 2020; 15(3):e0230332. PubMed ID: 32182260 [TBL] [Abstract][Full Text] [Related]
18. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. De Wals P; Lefebvre B; Defay F; Deceuninck G; Boulianne N Vaccine; 2012 Oct; 30(45):6416-20. PubMed ID: 22921290 [TBL] [Abstract][Full Text] [Related]
19. Ten years of experience with the pneumococcal non-typeable Lecrenier N; Marijam A; Olbrecht J; Soumahoro L; Nieto Guevara J; Mungall B Expert Rev Vaccines; 2020 Mar; 19(3):247-265. PubMed ID: 32195602 [No Abstract] [Full Text] [Related]
20. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age. Karppinen S; Toivonen L; Schuez-Havupalo L; Teros-Jaakkola T; Waris M; Auranen K; Palmu AA; Peltola V Vaccine; 2019 May; 37(22):2935-2941. PubMed ID: 31027929 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]